Abstract
This paper reviews bioactive peptides, biogenic peptides, opioid peptides, immunostimulating peptides, mineral soluble peptides, antihypertensive peptides and antimicrobial peptides originating from food materials and enzymatic hydrolysis of proteins. Antihypertensive peptides are extensively reviewed and have been divided into angiotensin Iconverting enzyme inhibitory peptides and others. These peptides are produced in the enzymatic hydrolysate of treated food materials such as milk, animal and fish meat, maize, wheat, soybeans and egg, and also from microbe-fermented products. Peptides with strong antihypertensive effects on spontaneously hypertensive rats are discussed and are divided into high and low angiotensin Iconverting enzyme inhibitory activities. In addition, new topics from our studies on antihypertensive peptides are introduced. Efficacies of these peptides in clinical studies and differences with medicinal substances are summarized. Recent studies in this area shown the possibility of using biogenic peptides for improvements in treatment or prevention of hypertension.
Keywords: angiotensin I-converting enzyme, aceI peptide, spontaneously hypertensive rats, concentration of peptide showing, inhibition of ace activity
Current Pharmaceutical Design
Title: Biogenic Peptides and Their Potential Use
Volume: 9 Issue: 16
Author(s): Naoyuki Yamamoto, Masahiro Ejiri and Seiichi Mizuno
Affiliation:
Keywords: angiotensin I-converting enzyme, aceI peptide, spontaneously hypertensive rats, concentration of peptide showing, inhibition of ace activity
Abstract: This paper reviews bioactive peptides, biogenic peptides, opioid peptides, immunostimulating peptides, mineral soluble peptides, antihypertensive peptides and antimicrobial peptides originating from food materials and enzymatic hydrolysis of proteins. Antihypertensive peptides are extensively reviewed and have been divided into angiotensin Iconverting enzyme inhibitory peptides and others. These peptides are produced in the enzymatic hydrolysate of treated food materials such as milk, animal and fish meat, maize, wheat, soybeans and egg, and also from microbe-fermented products. Peptides with strong antihypertensive effects on spontaneously hypertensive rats are discussed and are divided into high and low angiotensin Iconverting enzyme inhibitory activities. In addition, new topics from our studies on antihypertensive peptides are introduced. Efficacies of these peptides in clinical studies and differences with medicinal substances are summarized. Recent studies in this area shown the possibility of using biogenic peptides for improvements in treatment or prevention of hypertension.
Export Options
About this article
Cite this article as:
Yamamoto Naoyuki, Ejiri Masahiro and Mizuno Seiichi, Biogenic Peptides and Their Potential Use, Current Pharmaceutical Design 2003; 9 (16) . https://dx.doi.org/10.2174/1381612033454801
DOI https://dx.doi.org/10.2174/1381612033454801 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cartilage Oligomeric Matrix Protein: Matricellular and Matricrine Signaling in Cardiovascular Homeostasis and Disease
Current Vascular Pharmacology A Proposal----The Renal Kallikrein-Kinin System as a Compensating System for Salt Accumulation after Excess Salt Intake
Current Hypertension Reviews Future Treatment for COPD: Targeting Oxidative Stress and its Related Signal
Recent Patents on Inflammation & Allergy Drug Discovery Recent Progress in Signal Transduction Research of the Angiotensin II Type-1 Receptor: Protein Kinases, Vascular Dysfunction and Structural Requirement
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry High-dose Vitamin D Supplementation on Type 1 Diabetes Mellitus Patients: Is there an Improvement in Glycemic Control?
Current Diabetes Reviews Endogenous Bufadienolide, Blood Pressure and Alcohol Withdrawal
Current Hypertension Reviews Leptin and Vascular Smooth Muscle
Current Vascular Pharmacology Pulmonary Hemorrhage in Patients with Systemic Lupus Erythematosus
Current Respiratory Medicine Reviews subject Index To Volume 3
Current Drug Metabolism Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients
Current Drug Safety Cardiovascular Aspect of Beta-Thalassaemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolomic and Imaging: A Literature Review
Current Medical Imaging Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease
Protein & Peptide Letters Emerging Role of Bone Morphogenetic Proteins as a Context Dependent Pro-Angiogenic Cue
Current Angiogenesis (Discontinued) Releasing the Genie in the Bottle: Molecular Signaling with Hydrogen Sulfide
Current Neurovascular Research Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence
Current Vascular Pharmacology